|
Today's Headlines
Self-management has small effects on pain and disability in people with low back pain, according to a study published online in Arthritis Care & Research. » Full article
|
|
Prostaglandin inhibitors, such as celecoxib (Celebrex, Pfizer) and indomethacin (Indocin, Merck and Lundbeck) and calcium channel blockers, such as nifedipine and nicardipine (Cardene, Cornerstone Therapeutics) had the highest probability of delaying premature labor by 48 hours and improving maternal and neonatal outcomes, according to a systemic review and network meta-analysis published in a recent issue of BMJ. » Full article
|
|
FDA has approved cabozantinib (Cometriq, Exelixis) for the treatment of progressive, metastatic medullary thyroid cancer.
» Full article
|
|
The Obama administration moved ahead to implement provisions in the healthcare law that would make it illegal for insurance companies to deny coverage for those with pre-existing conditions. Other provisions of the Affordable Care Act also would make it easier for consumers to compare health plans and easier for employers to promote and encourage employee wellness.
» Full article
|
|
CONTINUING EDUCATION
Welcome to the third activity of our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The November activity will cover oral antidiabetes agents and noninsulin injectables for diabetes care.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.
|
|
ADVERTISEMENT
PAC Delivers More Predictable GER than AWP -
 click here to see example
New drug price type, Predictive Acquisition Cost (PAC), delivers more predictable and stable generic effective rate (GER) than Average Wholesale Price (AWP).
Click here to see a scenario illustrating how PAC compares to AWP for GER variability across drug groups.See example now. |
|
EDITOR'S PICK
Dimethyl fumarate is an investigational drug being studied for the treatment of relapsing-remitting multiple sclerosis (RRMS). The mechanism of action includes anti-inflammatory action as well as modulation of cellular oxidative response through nuclear-related factor E2-related factor 2 pathways. This agent is an oral formulation that lacks significant drug interactions, although it may be best administered prior to meals. Based on phase 2 and phase 3 clinical trials, dimethyl fumarate 240 mg 2 or 3 times daily is superior to placebo in reducing clinical and radiologic disease progression, annualized relapse rates, and new lesions on magnetic resonance imaging. Dimethyl fumarate appears to be safe; the most common adverse effects observed with the use of this drug are flushing and gastrointestinal side effects. A long-term, phase 3 extension study currently under way will provide more insight as to its safety and efficacy.
» Full article
|
|
|
Like
Tweet
